本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Akari Therapeutics PLC

11.30
+0.42003.86%
盤後12.621.32+11.68%19:57 EDT
成交量:13.52萬
成交額:149.95萬
市值:2,200.11萬
市盈率:-0.71
高:11.50
開:10.51
低:10.51
收:10.88
52周最高:49.60
52周最低:3.02
股本:194.70萬
流通股本:69.45萬
量比:1.13
換手率:19.46%
股息:- -
股息率:- -
每股收益(TTM):-15.9015
每股收益(LYR):-20.5537
淨資產收益率:-140.09%
總資產收益率:-19.10%
市淨率:1.18
市盈率(LYR):-0.55

資料載入中...

2024/03/05

重要事件披露

Form 8-K - Current report
2024/01/05

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/01/03

重要事件披露

Form 8-K - Current report
2023/10/25

SEC問詢函

Form CORRESP - Correspondence
2023/10/20

超過5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/10/13

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/31

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2023/05/01

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2023/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/11/07

SEC問詢函

CORRESP [Cover] - Correspondence
2022/11/04

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2022/10/12

招股説明書

F-1 - Registration statement for certain foreign private issuers
2022/05/16

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2022/02/14

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2022/01/14

超過5%披露

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
2021/08/30

SEC問詢函

CORRESP [Cover] - Correspondence
2021/04/21

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2021/02/16

超過5%披露

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
2020/12/30

SEC問詢函

CORRESP [Cover] - Correspondence